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In recent years, methamphetamine use has dramatically increased in Iran while there is a crucial misunderstanding
about the colloquial words related to methamphetamine among health providers, policy makers, clinicians, scholars
and people in the community. The word Crystal refers to methamphetamine in some parts of Iran while in some
other parts of the country, Crystal refers to a high purity street-level heroin which is called Kerack and its abuse is
epidemic. Methamphetamine and heroin Kerack are different drugs in Iran. Methamphetamine is a stimulant drug
while heroin Kerack is an opioid. Health providers especially clinicians and emergency medicine specialists should
consider colloquial words that Iranian drug users apply. Special training courses should be designed and
implemented for clinicians in Iran to inform them about methamphetamine and its frequently used colloquial
words in the community. This issue has important clinical and health implications.To the Editor:
Using opiates has a long history in Iran [1]. Opium and
its pharmacological and psychotropic effects were
known for several thousand years among Iranians [2] es-
pecially for managing general medical conditions such as
pain, colic problems, headaches, and implementing
anesthesia [3] but methamphetamine (MA) is a new
psychostimulant drug and its abuse has recently surged
in popularity [4,5] especially among young individuals in
Iran [6]. Methamphetamine is available in different
forms such as pure crystalline hydrochloride salt [7].
The main routes of methamphetamine administration
include smoking, sniffing, injection and ingestion [7].
In Iran, smoking is the most common route of
methamphetamine administration. Different medical
treatments such as Bupropion, Modafinil, Dextroam-
phetamine, and Naltrexone have been examined for
methamphetamine use treatment [8] but there is no
pharmacological therapy with established efficacy for the
treatment of this addictive disorder, nor is there any
medication approved by the regulatory authorities for
such treatment [9]. Cognitive-behavioral therapies in-
cluding the Matrix Model are the main methods for
treating methamphetamine use [10]. Recently, theCorrespondence: a.mehrjerdi@gmail.com
Iranian National Center for Addiction Studies (INCAS), Tehran University of
Medical Sciences, Tehran, Iran
© 2013 Alam Mehrjerdi; lincensee BioMed Cen
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortransition from the traditional patterns of using opium
and opium residues to methamphetamine smoking and/
or injection has changed in to a new health concern in
Iran [11].
A recent survey on 843 Iranian bodybuilders showed
that 13.3% reported a history of amphetamine use [12].
There is evidence that methamphetamine use has nega-
tively influenced opioid-dependent patients in metha-
done maintenance therapy. A recent study at the
methadone maintenance treatment clinic of Baharan
psychiatry hospital in Zahedan, Iran showed that meth-
amphetamine use increased among patients from 6% in
2009 to approximately 20% in 2011 [13]. Methampheta-
mine use could also contribute to spreading viral infec-
tions such as HIV and HCV among injecting drug users
in Iran [14]. The prevalence of methamphetamine use in
Iran has dramatically resulted in emerging metham-
phetamine-associated psychosis and intoxication [15,16].
There is evidence that methamphetamine use has also
imposed a crucial medical burden on the health sector
of Iran [17]. As a highly addictive psychostimulant drug,
the current increasing prevalence of methamphetamine
use in Iran is in part due to its somewhat easy and cost-
efficient syntheses in clandestine laboratories with inex-
pensive ingredients [11].
Methamphetamine is colloquially called Shisheh,
Shabu, Dar va Panjereh, Gach, Lachaki, Ice, and Crystal
in Iran. Shisheh is used as the most frequently usedtral. This is an Open Access article distributed under the terms of the Creative
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users in many parts of Iran but using the name Crystal
has widely implicated a crucial misunderstanding be-
tween the word methamphetamine and a common
street-level heroin (e.g. Iranian Kerack, not to be mis-
taken with Crack Cocaine) in clinical and therapeutic
settings, among health providers, policy makers, scholars
and in the community. In Iran, drugs which have been
named by drug users have sometimes similar western
names, but they have different chemical compositions
[18,19]. In some parts of Iran such as Khorasan prov-
ince, Crystal widely refers to methamphetamine which is
an addictive psychostimulant drug and its acute use in-
creases alertness, attention, energy and decreases anxiety
[20,21].
Acute methamphetamine use results in a number of
other effects on the sympathetic nervous system, includ-
ing hyper-tension, hyperthermia, increased breathing
rate, constriction of blood vessels, tachycardia, and
dialed pupils [22] but chronic methamphetamine use
and abuse result in severe psychosis [17]. A recent study
on fifty samples of methamphetamine obtained from
antinarcotics police seized in Iran showed that the
amounts of methamphetamine hydrochloride content in
the samples were 33%-95% [23]. In other parts of Iran,
the word Crystal widely refers to Iranian Kerack which
its chemical composition varies not only with metham-
phetamine content, but also in the adulterants added to
cut heroin. Iranian Kerack contains diacetylmorphine,
acetylcodeine, 6-monoacetylmorphine, caffeine, papaver-
ine, noscapine, dextromethorphan, morphine, codeine,
phenobarbital and diazepam [24].
It should be noted that using Crack Cocaine is not
prevalent in Iran and the word Kerack only refers to
Iranian heroin Kerack not Crack Cocaine. The current
misunderstanding is not limited to the community but it
is also common among clinicians, emergency medicine
specialists and scientific papers that have been recently
published on the emergence of methamphetamine use
problem by Iranian scholars. This issue has not received
scientific attention yet. Methamphetamine use treatment
is a current medical priority in Iran, and therefore, ex-
ploring precise names for methamphetamine is partly es-
sential in the procedure of diagnosis, designing and
implementing appropriate treatment and prevention
programs for this group of illicit drug users. For clini-
cians, health providers, clinical toxicologists and re-
searchers who work with methamphetamine users,
awareness of the exact meanings of the present metham-
phetamine-related names in the community is essential.
This issue is also important in critical situations includ-
ing emergency department settings of hospitals where
an immediate differential diagnosis of a type of drug
used is an urgent medical priority to manage a drug-related situation such as severe methamphetamine in-
toxication or psychosis. This issue could play an import-
ant role in providing an appropriate pharmacological
intervention.
For example, a recent study in the emergency depart-
ment setting of Loghman Hakim Hospital in Tehran
showed that severe dyspnea, sinus tachycardia with tach-
ypnea, and echocardiogram, severe systolic dysfunction
and heart failure were prevalent among methampheta-
mine-using patients [25]. Because of crucial health im-
plications, clinicians and health providers should take in
to consideration the types of drugs abused according to
the accurate individual meanings that each patient re-
ports. Special training courses should be designed and
implemented by health policy makers to inform clini-
cians and health professionals about common colloquial
methamphetamine-related words among Iranian drug
users. This strategy has been never implemented in Iran
and needs special attention in designing and tailoring
drug use treatment programs for this newly emerged
group of drug users in the country.
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